We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Extends Target Discovery Alliance with Cystic Fibrosis Foundation Therapeutics

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Galapagos Extends Target Discovery Alliance with Cystic Fibrosis Foundation Therapeutics"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Galapagos NV has announced the extension of the target discovery alliance between its service division BioFocus DPI and Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation.  This 15-month extension exceeds €800,000 in research fees and builds further on the alliance initiated in April 2005. 

As recently presented at the 20th Annual North American Cystic Fibrosis Conference in Denver, BioFocus DPI is applying its SilenceSelect adenoviral library and expertise in assay design to discover novel drug targets for the development of new cystic fibrosis therapies.
“The project to discover novel targets for cystic fibrosis is proceeding very well, and we are therefore pleased and proud that Cystic Fibrosis Foundation Therapeutics has extended the alliance.  This will enable BioFocus DPI to deliver validated targets as the basis for the development of new medicines,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.

“It is particularly gratifying that our target discovery engine is being applied to the unmet medical needs addressed by patient foundations such as the Cystic Fibrosis Foundation.”

“We are pleased with the quality of the results achieved to date in the alliance.  BioFocus DPI’s innovative target discovery platform is poised to deliver promising targets for the treatment of cystic fibrosis," said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation.

 “Our interactions with this team have been very positive and bode well for a successful outcome of this alliance.”